The wearable cardioverter-defibrillator vest: Indications and ongoing questions - ScienceDirect
Visual Abstracts | Cardiology Now
RC Webinar 2018: Results of the VEST Trial and it's Implications for Clinical Practice | Radcliffe Cardiology
PDF) Mitral-Valve Repair versus Replacement for Severe Ischemic Mitral Regurgitation
LifeVest Wearable Defibrillator Reduces Total Mortality By 36 Percent At 90 Days
Wearable Cardioverter–Defibrillator after Myocardial Infarction | NEJM
The wearable cardioverter-defibrillator vest: Indications and ongoing questions - ScienceDirect
Visual Abstracts | Cardiology Now
Wearable Cardioverter–Defibrillator after Myocardial Infarction | NEJM
Visual Abstracts | Cardiology Now
Visual Abstracts | Cardiology Now
ZOLL Symposium - EHRA 2018 - Dr. Jeffrey Olgin | Radcliffe Cardiology
Wearable Defibrillator Lowers Sudden Cardiac Death, But Only When You Wear It | UC San Francisco
Wearable Cardioverter–Defibrillator after Myocardial Infarction | NEJM
armyemdoc on X: "The results from our DEVICE trial are out in the @NEJM . In this RCT, direct laryngoscopy was inferior to video laryngoscopy for first-pass success. In fact, it was
Andrew J. Sauer, MD on LinkedIn: Wearable Cardioverter–Defibrillator after Myocardial Infarction | NEJM
Contemporary Drug Treatment of Advanced Heart Failure with Reduced Ejection Fraction | Drugs
LifeVest Wearable Defibrillator Reduces Total Mortality By 36 Percent At 90 Days
Wearable Cardioverter–Defibrillator after Myocardial Infarction | NEJM
Wearable Cardioverter-Defibrillator after MI | The incidence of sudden cardiac death is high during the early months after a myocardial infarction (MI). Whether the wearable cardioverter–defibrillator... | By The New England Journal
LifeVest for heart failure: Uses, how they work, and more
NEJM deputy editor John Jarcho, M.D., Live from ACC.18 | NEJM deputy editor and cardiologist John Jarcho, M.D., shares his thoughts on #ACC18 and on the MOMENTUM 3 trial, published by NEJM
RC Webinar 2018: Results of the VEST Trial and it's Implications for Clinical Practice | Radcliffe Cardiology
Visual Abstracts | Cardiology Now
Visual Abstracts | Cardiology Now
LifeVest Wearable Defibrillator Reduces Total Mortality By 36 Percent At 90 Days
ART, the largest ever randomized trial comparing CABG with bilateral Vs. single internal-thoracic-artery grafts
